retatrutide fda approval status october 2025 for Weight Loss: What It Is, How It Works & Side Effects Demand for Unapproved Weight-Loss Drug

Exenatide treatment did not change the eGFR significantly

Dehydration on a GLP-1 Is a Real Risk Heres How to Make Sure Youre Drinking Enough If youre on a GLP-1 medication for obesity or diabetes, you may experience common side effects like nausea, vomiting, diarrhea, or constipation

Egrifta (tesamorelin for injection) US Prescribing Information

The TRIUMPH-4 Phase 3 trial confirmed this: at 68 weeks, mean weight loss had reached 28.7% at 12 mg, an additional 4.5 percentage points beyond the 48-week Phase 2 result

In fact, this could lead to an increased risk of side effects, such as nausea, vomiting, low blood sugar, and other complications

What is the core difference between retatrutide and tirzepatide